Citadel Advisors’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Hold |
0
| – | – | – | 6772 |
|
|
2024
Q4 | – | Sell |
-52,846
| Closed | -$171K | – | 6644 |
|
|
2024
Q3 | $171K | Sell |
52,846
-31,467
| -37% | -$102K | ﹤0.01% | 4715 |
|
|
2024
Q2 | $253K | Buy |
84,313
+13,769
| +20% | +$41.3K | ﹤0.01% | 4459 |
|
|
2024
Q1 | $328K | Sell |
70,544
-305,114
| -81% | -$1.42M | ﹤0.01% | 4314 |
|
|
2023
Q4 | $1.56M | Sell |
375,658
-56,437
| -13% | -$234K | ﹤0.01% | 2619 |
|
|
2023
Q3 | $1.3M | Sell |
432,095
-155,699
| -26% | -$467K | ﹤0.01% | 2796 |
|
|
2023
Q2 | $1.45M | Sell |
587,794
-82,239
| -12% | -$202K | ﹤0.01% | 2685 |
|
|
2023
Q1 | $1.51M | Buy |
670,033
+401,017
| +149% | +$906K | ﹤0.01% | 2783 |
|
|
2022
Q4 | $939K | Sell |
269,016
-661,588
| -71% | -$2.31M | ﹤0.01% | 3270 |
|
|
2022
Q3 | $34.5M | Sell |
930,604
-16,809
| -2% | -$622K | 0.01% | 552 |
|
|
2022
Q2 | $18M | Buy |
947,413
+7,941
| +0.8% | +$151K | ﹤0.01% | 891 |
|
|
2022
Q1 | $25.4M | Buy |
939,472
+645,518
| +220% | +$17.4M | 0.01% | 764 |
|
|
2021
Q4 | $6.62M | Sell |
293,954
-81,898
| -22% | -$1.85M | ﹤0.01% | 1855 |
|
|
2021
Q3 | $9.85M | Buy |
375,852
+12,869
| +4% | +$337K | ﹤0.01% | 1458 |
|
|
2021
Q2 | $11.6M | Buy |
362,983
+352,522
| +3,370% | +$11.3M | ﹤0.01% | 1326 |
|
|
2021
Q1 | $368K | Buy |
10,461
+2,542
| +32% | +$89.4K | ﹤0.01% | 4844 |
|
|
2020
Q4 | $254K | Buy |
+7,919
| New | +$254K | ﹤0.01% | 4355 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 5162 |
|
|
2020
Q2 | – | Sell |
-320,072
| Closed | -$10.9M | – | 5192 |
|
|
2020
Q1 | $10.9M | Buy |
320,072
+239,906
| +299% | +$8.18M | ﹤0.01% | 941 |
|
|
2019
Q4 | $3.13M | Buy |
+80,166
| New | +$3.13M | ﹤0.01% | 1983 |
|